|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Market: Jordan
Espicom Business Intelligence Ltd, Oct 2011, Pages: 56
THE PHARMACEUTICAL MARKET: JORDAN - REVIEW
Jordan is a small but strategically located country in the Middle East, bordering Israel, Syria, Iraq and Saudi Arabia. Although it lacks the oil reserves of many of its neighbours and is relatively poor in comparison, it boasts good links with the West and is a key player on the local political scene. The stable economy and rapid population growth are both instrumental in the steady growth of the Jordanian pharmaceutical market. However, the small population naturally limits the market size.
Since its accession to the WTO, Jordan has demonstrated its commitment to WTO rules, in particular the TRIPS agreement, for example by recent improvements to, and enforcement of, IP protection. However, Jordan’s pharmaceutical regulatory environment has been criticised, mainly by international manufacturers, which accuse Jordan of regulatory discrimination in favour of domestic producers.
Jordan has a relatively strong level of domestic production. However, the majority is exported, resulting in a market still dependent on imports. Most imported pharmaceuticals are retail medicaments from countries located in Western Europe, such as Switzerland and Germany, while exports are primarily semi-finished and retail medicaments destined for other countries in the MENA region.
The largest pharmaceutical company in Jordan is Hikma Pharmaceuticals, with a market share of over 10.0%. The company has a number of manufacturing facilities in Jordan, as well as R&D facilities. In October 2010, Hikma announced it was to acquire an injectables business from a US company, which will significantly enhance the scope of the company’s injectables business worldwide. Previously, Hikma acquired an Algerian company in April 2010 and a Tunisian company in March 2010, strengthening its presence in the MENA region.
ENHANCED STRATEGIC INTELLIGENCE
These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
- The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
Also available
The Pharmaceutical Market: Egypt
The Pharmaceutical Market: Morocco
The Pharmaceutical Market: Turkey
The Pharmaceutical Market: Saudi Arabia
The Outlook for Pharmaceuticals in the Middle East and North Africa
Customers who bought this item also bought
The Outlook for Pharmaceuticals in the Middle East and North Africa
The Pharmaceutical Market: Pakistan
The Pharmaceutical Market: New Zealand
The Pharmaceutical Market: Austria
The Pharmaceutical Market: Morocco
The Pharmaceutical Market: Malaysia
The Pharmaceutical Market: Indonesia
The Pharmaceutical Market: Australia
The Pharmaceutical Market: Saudi Arabia
The Pharmaceutical Market: USA
|
|
|
|
